766 related articles for article (PubMed ID: 2145320)
1. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
2. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
4. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
[TBL] [Abstract][Full Text] [Related]
5. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
6. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
7. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Higo K; Karasawa A; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.
Fitzgerald DJ; Fragetta J; FitzGerald GA
J Clin Invest; 1988 Nov; 82(5):1708-13. PubMed ID: 3183064
[TBL] [Abstract][Full Text] [Related]
11. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
12. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT
J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
[TBL] [Abstract][Full Text] [Related]
13. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
Vandeplassche G; Hermans C; Van Dael L; Wouters L; De Clerck F
J Cardiovasc Pharmacol; 1993 Jan; 21(1):56-69. PubMed ID: 7678680
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
Ashton JH; Schmitz JM; Campbell WB; Ogletree ML; Raheja S; Taylor AL; Fitzgerald C; Buja LM; Willerson JT
Circ Res; 1986 Nov; 59(5):568-78. PubMed ID: 3542279
[TBL] [Abstract][Full Text] [Related]
15. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
Fitzgerald DJ; Wright F; FitzGerald GA
Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
[TBL] [Abstract][Full Text] [Related]
16. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
[TBL] [Abstract][Full Text] [Related]
17. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
18. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro.
O'Keefe EH; Liu EC; Greenberg R; Ogletree ML
Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
[TBL] [Abstract][Full Text] [Related]
20. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review.
Fiddler GI; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
